Thyroid Panel (TSH, Free T4, Total T4)
The LabCorp Thyroid Panel measures TSH, Free T4, and Total T4 from a single serum specimen, providing the TSH:Free T4 diagnostic axis — the primary clinical relationship in thyroid disease evaluation — alongside Total T4 as a binding-protein context marker.
3
Biomarkers
Blood (serum)
Sample
1–2 business days
Turnaround
No — fasting is not required. However: (1) patients on levothyroxine or T3-containing thyroid medications must take their morning dose AFTER the blood draw — pre-dose collection is mandatory for accurate monitoring; (2) biotin supplementation must be withheld for 48–72 hours before collection.
Fasting
What is the Thyroid Panel test?
The LabCorp Thyroid Panel measures TSH, Free T4, and Total T4 from a single serum specimen, providing a first-tier and second-tier thyroid assessment in one order. The panel is positioned between the efficiency of a standalone TSH — appropriate for population screening but providing no mechanistic or severity detail on its own — and the breadth of a comprehensive thyroid panel that includes Free T3, Reverse T3, and autoimmune antibodies. The LabCorp Thyroid Panel is the appropriate order when the clinical question is: does this patient have thyroid dysfunction and if so, what is its severity? — without yet requiring autoimmune characterisation, peripheral conversion assessment, or the full functional medicine thyroid marker spectrum. By combining TSH with Free T4 and Total T4 in a single order, the panel provides the TSH:Free T4 axis — the primary diagnostic relationship in thyroid medicine — alongside Total T4 as a contextualising marker for binding protein effects and an additional hyperthyroidism severity indicator. This eliminates the need for reflex ordering of Free T4 separately when TSH is abnormal, streamlining the diagnostic pathway. The inclusion of Total T4 alongside Free T4 is particularly useful when the practitioner needs to assess whether a binding protein alteration — from oestrogen therapy, pregnancy, or liver disease — is influencing the Free T4 result. When the clinical question extends to thyroid autoimmunity (Anti-TPO, Anti-TG), peripheral conversion capacity (Free T3, Reverse T3), or Graves' disease differentiation (TSI), the practitioner should order the Thyroid Panel Comprehensive rather than this panel.
What does the Thyroid Panel test measure?
Thyroid stimulating hormone is a 28 kDa heterodimeric glycoprotein secreted by anterior pituitary thyrotroph cells under hypothalamic TRH stimulation, and regulated by negative feedback from circulating free thyroid hormones — primarily Free T4 — acting at the pituitary and hypothalamic levels. TSH binds the TSH receptor (TSHR) on thyroid follicular cells, stimulating iodide uptake, thyroglobulin synthesis, thyroid peroxidase-mediated organification, and thyroid hormone secretion. Its relationship to Free T4 is logarithmic — small changes in circulating thyroid hormone produce large, amplified changes in TSH — making TSH the most sensitive single-point indicator of thyroid-pituitary feedback adequacy. TSH exhibits modest diurnal variation with a nocturnal peak and an early-morning nadir.
TSH is the primary anchor of the LabCorp Thyroid Panel — the most sensitive first-line marker for primary hypothyroidism, subclinical hypothyroidism, overt hyperthyroidism, and subclinical hyperthyroidism. An elevated TSH indicates pituitary detection of insufficient thyroid hormone; a suppressed TSH indicates suppression from excess thyroid hormone, exogenous thyroid replacement, or autonomous thyroid secretion. Interpreted alongside Free T4 and Total T4 within the panel, TSH establishes the axis of thyroid dysfunction and determines whether the Free T4 findings represent a primary thyroid gland disorder, adequate replacement, or over-treatment. The TSH:Free T4 relationship is the primary diagnostic axis of any thyroid panel.
Free T4 is the unbound, biologically available fraction of thyroxine — approximately 0.02–0.04% of total circulating T4 — representing the primary direct secretory product of the thyroid gland in its bioavailable form, uninfluenced by fluctuations in thyroid binding globulin (TBG), transthyretin, or albumin. T4 functions as a prohormone requiring peripheral monodeiodination by DIO1 and DIO2 deiodinase enzymes — primarily in liver, kidney, and skeletal muscle — to generate biologically active T3. Free T4 has a plasma half-life of approximately 7 days, making it a temporally stable indicator of thyroid secretory output and the gold-standard marker for assessing thyroid hormone adequacy independently of binding protein effects.
Free T4 is the definitive second-tier thyroid marker, measured alongside TSH to confirm the nature, mechanism, and severity of thyroid dysfunction identified on TSH. Elevated Free T4 with suppressed TSH confirms hyperthyroidism; reduced Free T4 with elevated TSH confirms overt primary hypothyroidism; normal Free T4 with elevated TSH defines subclinical hypothyroidism; low or normal Free T4 with normal or low TSH suggests central (secondary) hypothyroidism from pituitary or hypothalamic pathology. Free T4 is particularly informative in patients on oestrogen therapy where TBG elevation renders Total T4 unreliable, and in the post-partum period where thyroid function fluctuates rapidly. Within the LabCorp Thyroid Panel, Free T4 provides the definitive confirmation of the degree of thyroid hormone production — the clinical decision marker for treatment initiation and dose titration.
Total T4 is the combined measurement of protein-bound and free fractions of thyroxine in serum. Approximately 99.97% of circulating T4 is bound to thyroid binding globulin (TBG, approximately 70%), transthyretin (approximately 15%), and albumin (approximately 15%) — only the free fraction is biologically active. Total T4 is therefore substantially influenced by TBG concentration: elevated TBG from oestrogen exposure (OCP, HRT, pregnancy) raises Total T4; reduced TBG from androgen excess, corticosteroids, nephrotic syndrome, or severe liver disease lowers Total T4 — in all these states without truly reflecting thyroid hormone bioavailability. This TBG sensitivity is the primary limitation of Total T4 relative to Free T4 in the modern thyroid diagnostic landscape.
Total T4 retains specific clinical value within the LabCorp Thyroid Panel in three contexts. First, as a complementary marker in hyperthyroidism — Total T4 elevation above 12 µg/dL alongside suppressed TSH is consistent with overt hyperthyroidism; the degree of Total T4 elevation broadly tracks thyrotoxicosis severity. Second, in neonatal thyroid screening — where Total T4 is the established newborn screening marker alongside TSH. Third, in interpreting Free T4 discordance — when Free T4 and TSH appear inconsistent, Total T4 helps characterise whether binding protein alterations are influencing the Free T4 result. In most routine adult thyroid assessments, Free T4 is the clinically superior marker, and Total T4 plays a supporting interpretive role within this panel rather than standing alone as the primary thyroid hormone measurement.
Why is the Thyroid Panel test ordered?
- Initial thyroid evaluation with immediate Free T4 characterisation — patients with symptoms or signs suggesting thyroid dysfunction (fatigue, weight change, heat or cold intolerance, palpitations, cognitive change, constipation, hair loss) where obtaining TSH and Free T4 simultaneously avoids reflex delay and provides the primary diagnostic axis in a single draw
- Hypothyroidism diagnosis and severity characterisation — establishing TSH and Free T4 together at the point of diagnosis to classify overt versus subclinical hypothyroidism and guide the levothyroxine initiation dose calculation
- Hyperthyroidism evaluation — TSH, Free T4, and Total T4 simultaneously document the degree of thyroid hormone excess, establish the suppressed-TSH/elevated-Free T4 pattern confirming hyperthyroidism, and provide a Total T4 baseline before anti-thyroid drug therapy
- Levothyroxine dose adjustment monitoring — TSH and Free T4 together confirm both the pituitary feedback response and the free thyroxine level achieved on the current dose, preventing over- or under-dosing when monitoring replacement therapy
- Assessment in oestrogen-exposed patients (OCP, HRT, pregnancy) — Free T4 provides the binding-protein-independent thyroid hormone measurement; Total T4 contextualises the degree of TBG elevation by its elevation above the standard reference range
- Neonatal and paediatric thyroid evaluation — TSH and Total T4 are the established paediatric thyroid markers; the panel provides both in a single draw for congenital hypothyroidism investigation and thyroid disorder follow-up in children
- Post-thyroid surgery and radioiodine therapy follow-up — TSH and Free T4 together assess the adequacy of levothyroxine replacement following thyroid ablation, with Total T4 providing an additional cross-reference marker
- Differentiated thyroid cancer levothyroxine suppression monitoring — TSH and Free T4 together assess whether TSH suppression therapy (targeting TSH <0.1–0.5 mIU/L depending on risk stratification) is achieving suppression without excessive Free T4 elevation that would indicate over-replacement risk
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — fasting is not required. However: (1) patients on levothyroxine or T3-containing thyroid medications must take their morning dose AFTER the blood draw — pre-dose collection is mandatory for accurate monitoring; (2) biotin supplementation must be withheld for 48–72 hours before collection.
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
Standard venipuncture into a serum separator tube (SST / gold top). Document on the requisition form: (1) levothyroxine or other thyroid hormone medication — type, dose, and confirmation the morning dose was withheld; (2) biotin supplementation dose and whether withheld for ≥48 hours; (3) oestrogen-containing medications (OCP, HRT) — relevant for Total T4 and TBG interpretation; (4) pregnancy status and gestational age — trimester-specific TSH reference ranges apply; (5) current corticosteroids, amiodarone, or lithium — all alter thyroid panel results through distinct mechanisms; (6) acute illness or hospitalisation within 4 weeks — non-thyroidal illness pattern interpretation applies. # REVIEWER FLAG: Confirm LabCorp SST tube type, minimum serum volume, centrifugation and separation requirements, and per-analyte stability data for this panel before publication.
Specimen requirements
Minimum 1.0 mL serum for a 3-analyte panel (TSH, Free T4, Total T4). Centrifuge and separate serum from cells within 2 hours of collection. Stable at 2–8°C for up to 7 days; stable frozen at −20°C for extended storage. # REVIEWER FLAG: Confirm minimum volume requirements with LabCorp — confirm whether a single SST provides sufficient serum volume for all three analytes.
What can affect Thyroid Panel results?
High-dose biotin competitively inhibits streptavidin-biotin immunoassay chemistry, producing falsely suppressed TSH and potentially falsely altered Free T4 and Total T4 in platforms using biotin-streptavidin binding. The resultant pattern — suppressed TSH with apparent Free T4 elevation — mimics hyperthyroidism and has caused inappropriate anti-thyroid drug prescription in reported clinical cases. Biotin supplementation must be withheld for a minimum of 48–72 hours before specimen collection on this panel. # REVIEWER FLAG: Confirm LabCorp assay platforms for TSH, Free T4, and Total T4 — biotin interference magnitude and direction (suppression vs elevation) is assay-design-specific.
TBG-altering conditions affect Total T4 substantially while leaving Free T4 relatively unaffected. Oestrogen therapy (OCP, HRT) and pregnancy increase hepatic TBG synthesis, elevating Total T4 without reflecting true thyroid hormone excess — a normal TSH and Free T4 alongside elevated Total T4 in an oestrogen-exposed patient confirms TBG excess as the mechanism. Androgen excess, systemic corticosteroids, nephrotic syndrome, and severe liver disease reduce TBG, lowering Total T4 without indicating hypothyroidism. Within this panel, the Free T4:Total T4 relationship provides contextual evidence for TBG alteration when the two are discordant.
Oral levothyroxine produces a transient postabsorptive Free T4 and Total T4 peak 2–4 hours after ingestion, transiently suppressing TSH below the steady-state monitoring level. Monitoring specimens must always be collected as pre-dose (trough) draws — before the morning levothyroxine dose. Failure to collect pre-dose produces a spurious Free T4 elevation and TSH suppression suggesting over-replacement in a potentially well-controlled patient.
Acute severe systemic illness, major surgery, starvation, and physiological stress suppress TSH through cytokine-mediated hypothalamic-pituitary suppression and shift T4 metabolism toward rT3 production — lowering Total T4 (negative acute phase reactant), lowering Free T4 to a lesser degree, and producing a pattern that can resemble primary hypothyroidism or central hypothyroidism if interpreted without clinical context. The characteristic pattern is low or normal TSH alongside low Total T4 and low-normal Free T4 in an acutely unwell patient. Thyroid testing should ideally be deferred until 4–6 weeks after acute illness recovery.
FDH is an autosomal dominant condition in which a mutant albumin variant has abnormally high T4-binding affinity, elevating Total T4 and certain Free T4 immunoassay results (particularly analogue assay platforms) without true hyperthyroidism — TSH remains normal. This condition is not rare — it affects approximately 1 in 10,000 individuals — and is clinically significant because it can produce an apparently elevated Free T4 alongside normal TSH that may prompt unnecessary hyperthyroidism investigation. Equilibrium dialysis Free T4 is the discriminating assay in suspected FDH.
Human anti-animal antibodies — particularly human anti-mouse antibodies (HAMA) — can interfere with TSH and Free T4 sandwich immunoassays, producing either falsely elevated or falsely suppressed TSH results inconsistent with clinical status. HAMA exposure occurs through therapeutic monoclonal antibody treatment, diagnostic imaging agents, or occupational animal exposure. When TSH and Free T4 appear clinically discordant without explanation, serial dilution or heterophile antibody blocking tube testing at the laboratory can identify this interference.
What do Thyroid Panel results mean?
Elevated
Elevated TSH with normal Free T4 and normal Total T4 = subclinical hypothyroidism — treatment indicated when TSH >10 mIU/L, when symptomatic, when Anti-TPO positive (requires add-on), or when planning pregnancy; monitor 3–6 monthly when TSH 4.5–10 mIU/L and asymptomatic. Elevated TSH with low Free T4 and low Total T4 = overt primary hypothyroidism — levothyroxine initiation indicated. Elevated TSH with elevated Free T4 = pituitary resistance to thyroid hormone or TSH-secreting pituitary adenoma — rare; refer to endocrinology. Elevated Free T4 and Total T4 with suppressed TSH = overt hyperthyroidism — aetiology characterisation with Anti-TPO and TSI (add-on test) required before treatment selection. Elevated Total T4 alone with normal Free T4 and normal TSH = TBG excess from oestrogen therapy, pregnancy, or acute hepatitis — no thyroid pathology.
Normal
A fully normal panel — TSH 0.45–4.50 mIU/L, Free T4 0.82–1.77 ng/dL, Total T4 4.5–12.0 µg/dL — confirms euthyroid status and effectively excludes primary hypothyroidism and overt hyperthyroidism. In a symptomatic patient with a fully normal panel, primary thyroid dysfunction is unlikely as the dominant cause and alternative diagnostic pathways are appropriate. Practitioners who require autoimmune thyroid status (Hashimoto's, Graves' risk), peripheral conversion assessment (Free T3, Reverse T3), or the functional medicine marker set should order the Thyroid Panel Comprehensive as the next step.
Reduced
Low Free T4 with suppressed TSH = central (secondary) hypothyroidism from pituitary or hypothalamic failure — urgent pituitary assessment and ACTH/cortisol evaluation required before levothyroxine is initiated. Low or normal TSH with low Free T4 and low Total T4 in an unwell patient = non-thyroidal illness syndrome — defer reinterpretation until clinical recovery. Low Total T4 with normal Free T4 and normal TSH = reduced TBG from androgen excess, corticosteroids, or nephrotic syndrome — not clinically significant from a thyroid perspective. Suppressed TSH with elevated Free T4 and elevated Total T4 = overt hyperthyroidism — Anti-TPO and TSI required to characterise aetiology.
Note: Total T4 is TBG-dependent — its interpretation requires knowledge of the patient's oestrogen exposure, pregnancy status, and binding protein health; it cannot be used as a reliable standalone thyroid hormone marker in these contexts. The most important clinical caveat for this panel is that it cannot detect thyroid autoimmunity (Anti-TPO, Anti-TG) or characterise Graves' disease (TSI), peripheral conversion impairment (Free T3), or Reverse T3 burden — the clinical questions that require the comprehensive panel. Central hypothyroidism produces a pattern — low Free T4 with low or normal TSH — that cannot be distinguished from non-thyroidal illness syndrome on this panel alone without clinical context; both require the same specimen pattern and clinical history is the discriminator. Biotin interference remains the most common source of spurious panel results and is frequently unrecognised.
Frequently asked questions
The LabCorp Thyroid Panel measures three markers from a single serum draw: TSH (the pituitary's thyroid-stimulating signal — the most sensitive indicator of thyroid dysfunction), Free T4 (the biologically available thyroxine fraction produced by the thyroid gland, independent of binding proteins), and Total T4 (the combined bound and free thyroxine, which provides binding protein context). Together they diagnose and characterise hypothyroidism and hyperthyroidism, monitor levothyroxine therapy, and identify binding protein effects from oestrogen or pregnancy.
How to access the Thyroid Panel test
The Thyroid Panel reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: May 24, 2026
Last reviewed: May 24, 2026
- Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults. Thyroid. (2012)
- Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism. Thyroid. (2016)
- Koulouri O, et al. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab. (2013)
- Stockigt JR. Free thyroid hormone measurement: a critical appraisal. Endocrinol Metab Clin North Am. (2001)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
thyroid endocrine
Comprehensive Thyroid Panel
The Thyroid Panel Comprehensive measures the full thyroid hormone axis in a single serum draw — TSH, Free T4, Free T3, Reverse T3, Total T3, Anti-TPO, Anti-Thyroglobulin, and TSI — providing simultaneous assessment of thyroid hormone production, peripheral T4-to-T3 conversion capacity, Reverse T3 burden, thyroid autoimmunity aetiology (Hashimoto's thyroiditis and Graves' disease), and TSH…
thyroid endocrine
TSH
The TSH test measures Thyroid Stimulating Hormone produced by the anterior pituitary gland. It is the recommended first-line screening test for thyroid dysfunction, with elevated TSH indicating primary hypothyroidism and suppressed TSH indicating hyperthyroidism. TSH alone does not assess T4-to-T3 conversion or exclude central hypothyroidism.
thyroid endocrine
Free T3
The Free T3 test measures free triiodothyronine, the unbound and biologically active fraction of T3, in serum. It is primarily indicated for assessing the severity of hyperthyroidism, detecting T3 toxicosis, and characterising non-thyroidal illness syndrome. TSH and Free T4 remain the first-line markers for thyroid screening and hypothyroidism.